[go: up one dir, main page]

WO1996039136A1 - Transdermal formulation comprising ropinirole - Google Patents

Transdermal formulation comprising ropinirole Download PDF

Info

Publication number
WO1996039136A1
WO1996039136A1 PCT/EP1996/002435 EP9602435W WO9639136A1 WO 1996039136 A1 WO1996039136 A1 WO 1996039136A1 EP 9602435 W EP9602435 W EP 9602435W WO 9639136 A1 WO9639136 A1 WO 9639136A1
Authority
WO
WIPO (PCT)
Prior art keywords
ropinirole
transdermal
transdermal formulation
formulation
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002435
Other languages
French (fr)
Inventor
Anil Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to EP96917499A priority Critical patent/EP0831810A1/en
Priority to JP9500145A priority patent/JPH11506462A/en
Publication of WO1996039136A1 publication Critical patent/WO1996039136A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to a transdermal formulation comprising 4-(2-di-n- proylaminoethyl)-2(3H)-indolone and for the use thereof in treating Parkinson's Disease.
  • EP 0 299 602- A2 further discloses that other forms of administration may be considered for ropinirole and salts thereof, including parenteral, rectal and transdermal.
  • a typical transdermal formulation is said to comprise a conventional aqueous or non-aqueous vehicle, for example, a cream, ointment lotion or paste in the form of a medicated plaster, patch or membrane. There is however no further guidance on suitable transdermal formulations or expected dosage for such formulations.
  • a transdermal formulation offers the advantage of a more convenient mode of administration of the drug substance, thereby potentially enhancing patient compliance.
  • drug substance is released in a more controlled fashion, over a prolonged period, offering potential therapeutic advantges.
  • transdermal formulations able to provide a therapeutically useful amount of the drug may be prepared by using the free base form of the compound, in comparison to the hydrochloride salt preferred for tablet formulation.
  • the present invention provides for a transdermal formulation comprising ropinirole (free base).
  • Such formulations offer not only a more convenient method of administration but also possible therapeutic benefits and improved side effect profile.
  • transdermal formulations are well known in the art (see for instance Percutaneous Absorption and Transdermal Therapy, K A Walters, March 1986; Pharmaceutical Dosage Forms and Drug Delivery Systems, (5th Ed.), H C. Ansel and N G. Popovich, Chapter 9, Lea and Febiger (1990), pages 307 to 320 and Sustained and Controlled Release Drug Delivery Systems, ed J R Robinson, Marcel Dekker Inc., New York (1978), pages 579 et seq.).
  • Two main types of transdermal delivery devices are currentiy marketed and these are classified as matrix and membrane systems (Physicochemical Principles of Pharmacy, A.T. Florence and D. Attwood, 2nd Edition, Macmillan, 1993, page 331).
  • the drug is dispersed in a release controlling matrix which consists either of a gel or an adhesive film.
  • Membrane systems generally consist of a drug reservoir, a rate-controlling membrane and an adhesive layer. In both cases the active is dissolved or suspended in a vehicle which then forms an integral part of the delivery device.
  • the drug substance may be dissolved or suspended in a liquid or a gel.
  • Suitable vehicles include both aqueous and non-aqueous vehicles, for instance saline and saline/propylene glycol (1:1).
  • a penetration enhancer may also be added, if appropriate.
  • the transdermal formulation is provided in the form of a medicated plaster, patch or membrane, preferably a patch.
  • the patch is between 10 and 50cm 2 , preferably between 20 and 40 cm 2 .
  • the patch will be provided with a pharmaceutically accetable adhesive layer so that it can retained on the skin of the user.
  • the adhesive effect of the layer will be reversible such that the patch will remain in place for the lifetime of the patch but still be easy for the Parkinson's Disease patient to apply and remove.
  • ropinirole free base may be generated in situ in the transdermal formulation, from a suitable ropinirole salt such as ropinirole hydrochloride, suitably immediately prior to use.
  • a suitable ropinirole salt such as ropinirole hydrochloride
  • this may be achieved by including in the formulation a base which would be brought into contact with the ropinirole salt to effect formation of the free base.
  • the salt and base are kept apart, to avoid premature reaction, for instance in a two compartment reservoir having a rupturable barrier between the two compartments.
  • a preliminary evaluation of transdermal candidates is performed prior to incorporation in such a device.
  • the most effective method is to determine drug penetration from suspensions or solutions using a human skin in vitro model, such as the Franz cell (Dematological Formulations: Percutaneous Abso ⁇ tion, B W Barry, Marcel Dekker (1983), page 245).
  • the delivery profile will provide a steady rate delivery.
  • a compartmentalised rate controlled device may be used.
  • a suitable target skin flux will be in the range 5 to 25, preferably 10 to 15 ⁇ g/cm 2 hr.
  • the amount of ropinirole administered through a transdermal formulauon according to the present invention will be selected so that it will provide an amount of ropinirole substantially similar to that obtained following conventional oral administration of a tablet formulation, that is substantially similar to that obtained following administration of between 0.1 and lOmg of ropinirole (expressed as the free base) three times a day, assuming about 50% bioavailablity.
  • the transdermal formulation is provided in unit dose form.
  • the transdermal formulation is provided in a range of dosage amounts, for instance to allow for titration of an individual patient's drug requirement.
  • a suitable dose may be obtained by combining different strength formulations.
  • the unit dose form will provide sufficient drug substance for a 24 hour period (including, if appropriate 'off time'), to permit once-a-day application of the formulation. Suitably such application may be in the evening.
  • the transdermal formulation will be administered for a period of continuous therapy.
  • Transdermal formulations according to the present invention will be of use in therapy, in particular treating Parkinson's Disease. Accordingly, in a further aspect, the present invention provides for the manufacture of a medicament comprising ropinirole (free base) adapted for a transdermal administration for use in treating Parkinson's Disease.
  • the transdermal formulation may be used in patients in all stages of disease and/or as therapy after initial dose titration with a conventional tablet.
  • Ropinirole hydrochloride (190gm), water (1.35L) and ammonia (160mL,SG 0.88) were added to a flask fitted with stirrer and nitrogen bleed. This mixture was then stirred at ambient for ca 2hours and then extracted with dichloromethane (lx500mL, lx 250mL, lx 200mL). All the organic extracts were combined, washed with brine (3x50mL) and dried over with magnesium sulphate (if free water was still present). Removal of the solvent by evaporation under reduced pressue gave a light brown solid (142gm, 85% yield).
  • a typical patch comprising a membrane is as follows:
  • a backing layer of aluminized plastic that is impermeable to ropinirole; drug reservoir containing ropinirole (30 to 60mg/ml) in a saline/propylene glycol (1:1) vehicle; ethylene- vinyl acetate copolymer membrane that is permeable to ropinirole; and a layer of hypoallergenic silicone adhesive; plus a protective peel strip covering the adhesive surface.
  • a typical patch comprising a matrix is as follows:
  • ropinirole as the free base
  • a ropinirole salt for formulation into a transdermal delivery system was initially evaluated by determining drug penetration from suspensions or solutions using a human skin in vitro model.
  • the in vitro percutaneous penetration method utilised saturated solutions of ropinirole hydrochloride and ropinirole free base.
  • the in vitro set up consisted of modified Franz cells (Dematological Formulations: Percutaneous Absorption. B.W. Barry, Marcel Dekker, 1983, 245) with full thickness human abdominal skin and a receptor of 0.9% saline.
  • the vehicles tested were ropinirole and its hydrochloride salt in aqueous 0.9% saline and aqueous 0.9% saline/propylene glycol (50:50). Samples were taken from the receptor at intervals and analysed for ropinirole content. From these results the concentration of ropinirole penetrating human skin with time could be determined.
  • Penetration of the free base appears to be 20 fold better than the salt from the 0.9% saline vehicle and 40 fold better from the PG: saline vehicle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Transdermal formulations comprising ropinirole for use in treating Parkinson's Disease.

Description

TRANSDERMAL FORMULATION COMPRISING ROPINIROLE
The present invention relates to a transdermal formulation comprising 4-(2-di-n- proylaminoethyl)-2(3H)-indolone and for the use thereof in treating Parkinson's Disease.
4-(2-di-n-proylaminoethyl)-2(3H)-indolone (hereinafter referred to by its approved name Ropinirole) is the compound of formula (I):
Figure imgf000003_0001
This compound was first disclosed in EP 0 113 964- A 1 (SmithKline Beckman Corp) as a peripheral, pre-synaptic U2-agonist, suitable for use in treating angina and hypertension. Subsequently, it was also shown to have central effects, as a post- synaptic U2-agonist in the brain (EP 0 299 602-A2, Smith Kline & French Laboratories). Furthermore, tolerance was developed to the peripheral effects. These central effects have led to the compound (as the hydrochloride salt) being developed for use in treating Parkinson's Disease, by oral administration of a tablet formulation.
EP 0 299 602- A2 further discloses that other forms of administration may be considered for ropinirole and salts thereof, including parenteral, rectal and transdermal. A typical transdermal formulation is said to comprise a conventional aqueous or non-aqueous vehicle, for example, a cream, ointment lotion or paste in the form of a medicated plaster, patch or membrane. There is however no further guidance on suitable transdermal formulations or expected dosage for such formulations.
A transdermal formulation offers the advantage of a more convenient mode of administration of the drug substance, thereby potentially enhancing patient compliance. In addition, drug substance is released in a more controlled fashion, over a prolonged period, offering potential therapeutic advantges.
It has now been found that improved transdermal formulations able to provide a therapeutically useful amount of the drug may be prepared by using the free base form of the compound, in comparison to the hydrochloride salt preferred for tablet formulation.
Accordingly, the present invention provides for a transdermal formulation comprising ropinirole (free base).
Such formulations offer not only a more convenient method of administration but also possible therapeutic benefits and improved side effect profile.
Suitable transdermal formulations are well known in the art (see for instance Percutaneous Absorption and Transdermal Therapy, K A Walters, March 1986; Pharmaceutical Dosage Forms and Drug Delivery Systems, (5th Ed.), H C. Ansel and N G. Popovich, Chapter 9, Lea and Febiger (1990), pages 307 to 320 and Sustained and Controlled Release Drug Delivery Systems, ed J R Robinson, Marcel Dekker Inc., New York (1978), pages 579 et seq.). Two main types of transdermal delivery devices are currentiy marketed and these are classified as matrix and membrane systems (Physicochemical Principles of Pharmacy, A.T. Florence and D. Attwood, 2nd Edition, Macmillan, 1993, page 331). In matrix systems, the drug is dispersed in a release controlling matrix which consists either of a gel or an adhesive film. Membrane systems generally consist of a drug reservoir, a rate-controlling membrane and an adhesive layer. In both cases the active is dissolved or suspended in a vehicle which then forms an integral part of the delivery device. The drug substance may be dissolved or suspended in a liquid or a gel. Suitable vehicles include both aqueous and non-aqueous vehicles, for instance saline and saline/propylene glycol (1:1). A penetration enhancer may also be added, if appropriate.
Suitably, the transdermal formulation is provided in the form of a medicated plaster, patch or membrane, preferably a patch. Suitably the patch is between 10 and 50cm2, preferably between 20 and 40 cm2. The patch will be provided with a pharmaceutically accetable adhesive layer so that it can retained on the skin of the user. Preferably the adhesive effect of the layer will be reversible such that the patch will remain in place for the lifetime of the patch but still be easy for the Parkinson's Disease patient to apply and remove.
In a further aspect, ropinirole free base may be generated in situ in the transdermal formulation, from a suitable ropinirole salt such as ropinirole hydrochloride, suitably immediately prior to use. Suitably this may be achieved by including in the formulation a base which would be brought into contact with the ropinirole salt to effect formation of the free base. The salt and base are kept apart, to avoid premature reaction, for instance in a two compartment reservoir having a rupturable barrier between the two compartments.
Suitably, a preliminary evaluation of transdermal candidates is performed prior to incorporation in such a device. The most effective method is to determine drug penetration from suspensions or solutions using a human skin in vitro model, such as the Franz cell (Dematological Formulations: Percutaneous Absoφtion, B W Barry, Marcel Dekker (1983), page 245).
Preferably, the delivery profile will provide a steady rate delivery. Alternatively, a compartmentalised rate controlled device may used. A suitable target skin flux will be in the range 5 to 25, preferably 10 to 15 μg/cm2 hr.
Suitably, the amount of ropinirole administered through a transdermal formulauon according to the present invention will be selected so that it will provide an amount of ropinirole substantially similar to that obtained following conventional oral administration of a tablet formulation, that is substantially similar to that obtained following administration of between 0.1 and lOmg of ropinirole (expressed as the free base) three times a day, assuming about 50% bioavailablity.
Suitably the transdermal formulation is provided in unit dose form. Suitably, the transdermal formulation is provided in a range of dosage amounts, for instance to allow for titration of an individual patient's drug requirement. A suitable dose may be obtained by combining different strength formulations. Suitably, the unit dose form will provide sufficient drug substance for a 24 hour period (including, if appropriate 'off time'), to permit once-a-day application of the formulation. Suitably such application may be in the evening. Suitably, the transdermal formulation will be administered for a period of continuous therapy.
Transdermal formulations according to the present invention will be of use in therapy, in particular treating Parkinson's Disease. Accordingly, in a further aspect, the present invention provides for the manufacture of a medicament comprising ropinirole (free base) adapted for a transdermal administration for use in treating Parkinson's Disease. The transdermal formulation may be used in patients in all stages of disease and/or as therapy after initial dose titration with a conventional tablet.
The invention will now be illustrated by the following examples. Description 1 - preparation of ropinirole
Ropinirole hydrochloride (190gm), water (1.35L) and ammonia (160mL,SG 0.88) were added to a flask fitted with stirrer and nitrogen bleed. This mixture was then stirred at ambient for ca 2hours and then extracted with dichloromethane (lx500mL, lx 250mL, lx 200mL). All the organic extracts were combined, washed with brine (3x50mL) and dried over with magnesium sulphate (if free water was still present). Removal of the solvent by evaporation under reduced pressue gave a light brown solid (142gm, 85% yield).
NMR [5H(CDC13)]: 0.9(6H,t),1.5(4H,m),2.7(3H,s)3.5(2H,s) 6.7-6.9(3H,m,Ar),8.6(2H,br,NH).
Example 1
A typical patch comprising a membrane is as follows:
a backing layer of aluminized plastic that is impermeable to ropinirole; drug reservoir containing ropinirole (30 to 60mg/ml) in a saline/propylene glycol (1:1) vehicle; ethylene- vinyl acetate copolymer membrane that is permeable to ropinirole; and a layer of hypoallergenic silicone adhesive; plus a protective peel strip covering the adhesive surface.
patch size = 20-40cm2 reservoir volume = 0.5- lml
Example 2
A typical patch comprising a matrix is as follows:
backing foil; drug reservoir comprising a ropinirole/lactose trituration homogeneously dispersed in a hydrogel composed of water, glycerin, poly vinyl alcohol and polyvinylpyrrolidone; adhesive layer; and a release liner. Example 3 - in vitro Percutaneous Penetration of Ropinirole
The relative potential of ropinirole (as the free base) and a ropinirole salt for formulation into a transdermal delivery system was initially evaluated by determining drug penetration from suspensions or solutions using a human skin in vitro model.
The in vitro percutaneous penetration method utilised saturated solutions of ropinirole hydrochloride and ropinirole free base. The in vitro set up consisted of modified Franz cells (Dematological Formulations: Percutaneous Absorption. B.W. Barry, Marcel Dekker, 1983, 245) with full thickness human abdominal skin and a receptor of 0.9% saline. The vehicles tested were ropinirole and its hydrochloride salt in aqueous 0.9% saline and aqueous 0.9% saline/propylene glycol (50:50). Samples were taken from the receptor at intervals and analysed for ropinirole content. From these results the concentration of ropinirole penetrating human skin with time could be determined.
Results
Figure imgf000007_0001
(SEM) = Standard Error of Mean [Rel to 1] = Skin penetration relative to formulation 1 PG = Propylene glycol Conclusions
Penetration of the free base appears to be 20 fold better than the salt from the 0.9% saline vehicle and 40 fold better from the PG: saline vehicle.
Using this test system, 10-20 μg of the free base penetrated through the skin over a 24 hour period. Thus, with a patch of 30 cm2, potentially 300-600 μg of drug could be delivered, to give therapeutically effective blood levels of ropinirole.

Claims

Claims
1. A transdermal formulation comprising ropinirole (free base).
2. A transdermal formulation as claimed in claim 1 which has a target skin flux of from 5 to 25 μg/cm2/hr.
2. A transdermal formulation as claimed in claim 1 in the form of a patch.
3. A transdermal formulation as claimed in claim 1 or 2 in the form of a unit dosage, comprising between 1 and 20 mg of ropinirole.
4. A transdermal formulation as claimed in any one of claims 1 to 3 in which ropinirole free base is generated in situ.
5. A transdermal formulation as claimed in any one of claim 1 to 4 adapted for once- a-day application.
6. The manufacture of a medicament comprising ropinirole (free base) adapted for transdermal administration for treating Parkinson's Disease.
PCT/EP1996/002435 1995-06-06 1996-06-04 Transdermal formulation comprising ropinirole Ceased WO1996039136A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96917499A EP0831810A1 (en) 1995-06-06 1996-06-04 Transdermal formulation comprising ropinirole
JP9500145A JPH11506462A (en) 1995-06-06 1996-06-04 Transdermal formulation containing ropinirole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511366.8A GB9511366D0 (en) 1995-06-06 1995-06-06 Novel formulations
GB9511366.8 1995-06-06

Publications (1)

Publication Number Publication Date
WO1996039136A1 true WO1996039136A1 (en) 1996-12-12

Family

ID=10775543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002435 Ceased WO1996039136A1 (en) 1995-06-06 1996-06-04 Transdermal formulation comprising ropinirole

Country Status (4)

Country Link
EP (1) EP0831810A1 (en)
JP (1) JPH11506462A (en)
GB (1) GB9511366D0 (en)
WO (1) WO1996039136A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084A1 (en) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Transdermal therapeutic system for the treatment of Parkinson's syndrome containing D2 agonist and method for its production
WO2003011291A1 (en) * 2001-07-30 2003-02-13 Hexal Ag Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole
US7258871B2 (en) 2000-10-20 2007-08-21 Neurobiotec Gmbh Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
WO2008005240A3 (en) * 2006-06-29 2008-05-08 Jazz Pharmaceuticals Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof
WO2009082268A2 (en) 2007-12-21 2009-07-02 Alla Chem, Llc LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
WO2009112167A1 (en) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system having stabilized membrane
WO2010024717A1 (en) 2008-08-22 2010-03-04 Алла Xem, Ллс Ligand with a broad spectrum of pharmacological activity, a pharmaceutical composition, a medicinal agent and a method of treatment
US7927624B2 (en) 2000-04-14 2011-04-19 Jagotec Ag Hydrophilic/lipophilic polymeric matrix dosage formulation
EP2258355A4 (en) * 2008-02-27 2011-05-04 Hisamitsu Pharmaceutical Co PATCH
CN102361639A (en) * 2009-04-24 2012-02-22 久光制药株式会社 Adhesive patch-containing package bag and method for storing adhesive patch
WO2011132966A3 (en) * 2010-04-23 2012-04-12 아이큐어(주) Transdermal absorption preparation
EP2438917A4 (en) * 2009-05-21 2014-01-22 Hisamitsu Pharmaceutical Co TRANSDERMAL PREPARATION
CN103561737A (en) * 2011-05-31 2014-02-05 久光制药株式会社 Ropinirole-containing adhesive skin patch and packaged product thereof
US9155710B2 (en) 2011-05-31 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Ropinirole-containing patch and package thereof
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
US9186335B2 (en) 2002-07-30 2015-11-17 Ucb Pharma Gmbh Hot melt TTS for administering rotigotine
US9320728B2 (en) 2013-06-28 2016-04-26 Hisamitsu Pharmaceutical Co., Inc. Method for producing patch, patch and package
US9849095B2 (en) 2011-12-01 2017-12-26 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US10716763B2 (en) 2015-04-15 2020-07-21 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch containing ropinirole
US20210169849A1 (en) * 2019-04-17 2021-06-10 Vici Health Sciences LLC Liquid pharmaceutical compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (en) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease
WO2014084311A1 (en) 2012-11-30 2014-06-05 帝國製薬株式会社 Ropinirole-containing adhesive patch
JP6373061B2 (en) * 2014-05-23 2018-08-15 帝國製薬株式会社 Transdermal formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299602A2 (en) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited Use of indolone derivatives for the preparation of medicaments for the treatment of Parkinsons disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299602A2 (en) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited Use of indolone derivatives for the preparation of medicaments for the treatment of Parkinsons disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"FORMES PHARMACEUTIQUES NOUVELLES", 1988, LAVOISIER, PARIS, XP002013798 *
D.B. CALNE: "TREATMENT OF PARKINSON'S DISEASE", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 329, no. 14, 1993, pages 1021 - 1027, XP002013778 *
H.C. ANSEL ET AL.: "TRANSDERMAL DRUG DELIVERY SYSTEMS, OINTMENTS, CREAMS, LOTIONS, AND OTHER PREPARATIONS", PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS 5TH ED., CHAPTER 9, 1990, pages 307 - 320, XP002013779 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251844B2 (en) 1998-03-30 2019-04-09 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system and method of use thereof for treating parkinsonism
US10322093B2 (en) 1998-03-30 2019-06-18 Ucb Biopharma Sprl Method for producing a transdermal therapeutic system which contains a D2 agonist
US6884434B1 (en) 1998-03-30 2005-04-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
DE19814084B4 (en) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
DE19814084A1 (en) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Transdermal therapeutic system for the treatment of Parkinson's syndrome containing D2 agonist and method for its production
US7927624B2 (en) 2000-04-14 2011-04-19 Jagotec Ag Hydrophilic/lipophilic polymeric matrix dosage formulation
US8303986B2 (en) 2000-04-14 2012-11-06 Jagotec Ag Hydrophilic/lipophilic polymeric matrix dosage formulation
US8460706B2 (en) 2000-04-14 2013-06-11 Jagotec Ag Hydrophilic/lipophilic polymeric matrix dosage formulation
US7258871B2 (en) 2000-10-20 2007-08-21 Neurobiotec Gmbh Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
WO2003011291A1 (en) * 2001-07-30 2003-02-13 Hexal Ag Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole
US9186335B2 (en) 2002-07-30 2015-11-17 Ucb Pharma Gmbh Hot melt TTS for administering rotigotine
WO2008005240A3 (en) * 2006-06-29 2008-05-08 Jazz Pharmaceuticals Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof
WO2009082268A2 (en) 2007-12-21 2009-07-02 Alla Chem, Llc LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
EP2258355A4 (en) * 2008-02-27 2011-05-04 Hisamitsu Pharmaceutical Co PATCH
US8580281B2 (en) 2008-02-27 2013-11-12 Hisamitsu Pharmaceutical Co., Inc. Medicated patch
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
US8871249B2 (en) 2008-02-27 2014-10-28 Hisamitso Pharmaceutical Co., Inc. Medicated patch
US8882729B2 (en) 2008-03-11 2014-11-11 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system having stabilized membrane
WO2009112167A1 (en) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system having stabilized membrane
WO2010024717A1 (en) 2008-08-22 2010-03-04 Алла Xem, Ллс Ligand with a broad spectrum of pharmacological activity, a pharmaceutical composition, a medicinal agent and a method of treatment
CN102361639A (en) * 2009-04-24 2012-02-22 久光制药株式会社 Adhesive patch-containing package bag and method for storing adhesive patch
EP2438917A4 (en) * 2009-05-21 2014-01-22 Hisamitsu Pharmaceutical Co TRANSDERMAL PREPARATION
US9238025B2 (en) 2009-05-21 2016-01-19 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation comprising a ropinirole derivative
WO2011132966A3 (en) * 2010-04-23 2012-04-12 아이큐어(주) Transdermal absorption preparation
US9155710B2 (en) 2011-05-31 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Ropinirole-containing patch and package thereof
EP2716287A4 (en) * 2011-05-31 2014-11-26 Hisamitsu Pharmaceutical Co ADHESIVE TRANSDERMAL STAMP CONTAINING ROPINIROLE AND PACKAGED PRODUCT THEREFOR
US9918945B2 (en) 2011-05-31 2018-03-20 Hisamitsu Pharmaceutical Co., Inc. Ropinirole-containing patch and package thereof
CN103561737A (en) * 2011-05-31 2014-02-05 久光制药株式会社 Ropinirole-containing adhesive skin patch and packaged product thereof
US9849095B2 (en) 2011-12-01 2017-12-26 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US9320728B2 (en) 2013-06-28 2016-04-26 Hisamitsu Pharmaceutical Co., Inc. Method for producing patch, patch and package
US10716763B2 (en) 2015-04-15 2020-07-21 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch containing ropinirole
US20210169849A1 (en) * 2019-04-17 2021-06-10 Vici Health Sciences LLC Liquid pharmaceutical compositions

Also Published As

Publication number Publication date
JPH11506462A (en) 1999-06-08
EP0831810A1 (en) 1998-04-01
GB9511366D0 (en) 1995-08-02

Similar Documents

Publication Publication Date Title
EP0831810A1 (en) Transdermal formulation comprising ropinirole
JP2542026B2 (en) Flat treatment device and its manufacturing method
US4230105A (en) Transdermal delivery of drugs
US8017146B2 (en) Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised
Cleary Transdermal delivery systems: a medical rationale
CN102026629B (en) transdermal preparation
CA2563110A1 (en) Rivastigmine comprised in a transdermal therapeutic system for use in the treatment of dementia or alzheimer disease
JP2010500992A (en) Transcutaneous treatment method and transcutaneous treatment system for Alzheimer's disease
JPH0684304B2 (en) Transdermal system for timolol
AU2004206783B2 (en) Formulation and methods for the treatment of thrombocythemia
KR100764679B1 (en) Percutaneous Patches Containing Paroxetine
US6106856A (en) Transdermal delivery of calcium channel blockers, such as nifedipine
US20020127271A1 (en) Formulation for the treatment and/or prophylaxis of dementia
EP0918521B1 (en) Formulation for the treatment and/or prophylaxis of dementia
AU721101C (en) Formulation for the treatment and/or prophylaxis of dementia
EP1216036B1 (en) Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines
ES2309107T3 (en) DEVICE AND TRANSDERMIC METHODS FOR PHELODIPINE.
Hodade et al. Approach on Transdermal Drug Delivery System
JP2002521324A (en) Formulations for transdermal administration of fenoldopam
HK1021314B (en) Formulation for the treatment and/or prophylaxis of dementia
CN114502143A (en) Reduced lag time/ice spray
US20040258742A1 (en) Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
WO2018133010A1 (en) Transdermal absorption preparation and method for preparing same
MXPA98010421A (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
HUP9903064A2 (en) Transdermal pharmaceutical composition uhich conprises [r-(z)]-alfa-(methoxyimino)-alfa-(1-azabicyclo-[2.2.2.]oct-3-yl)acetoritrile and process for poducing this

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996917499

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 500145

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996917499

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996917499

Country of ref document: EP